Headache - medication overuse
Exam Tips
- Use the diagnostic numbers: >=15 headache days/month plus medication overuse for >3 months; >=10 days/month for triptans/opioids/ergots/combination analgesics, >=15 days/month for simple analgesics.
- In OSCEs, ask for exact monthly medication-day counts and classify each drug type; this is frequently missed.
- MOH usually has a normal neurological exam; always document red-flag screening to exclude dangerous secondary causes.
- Management marks come from explaining withdrawal, setting strict future acute-treatment limits (<=2 days/week), and planning follow-up with a headache diary.
- Know high-risk relapse groups: opioid overuse, long overuse duration, psychiatric comorbidity, and mixed migraine+tension phenotypes.
Definition
Medication overuse headache (MOH) is a secondary chronic headache disorder in which a person with a pre-existing primary headache (usually migraine, sometimes tension-type headache) develops headache on at least 15 days/month due to regular overuse of acute headache medicines for more than 3 months. Typical overuse thresholds are >=10 days/month for triptans, opioids, ergotamine, or combination analgesics, and >=15 days/month for simple analgesics (for example paracetamol or NSAIDs).
Pathophysiology
The mechanism is multifactorial: repeated exposure to acute analgesic/antimigraine drugs in a susceptible brain appears to drive central sensitization, altered pain-modulation networks, and neuronal hyperexcitability, leading to headache chronification. MOH is strongly linked to high baseline headache frequency and often mirrors the phenotype of the original headache disorder. Triptan overuse tends to produce MOH faster than simple analgesic overuse. Neurobiologically, changes in central nociceptive processing may improve after withdrawal (see Figure from standard headache textbook chapters on trigeminovascular sensitization).
Risk Factors
- Pre-existing migraine or tension-type headache (especially high baseline attack frequency)
- Frequent use of acute headache medication, particularly triptans, opioids, ergotamines, or combination analgesics
- Psychiatric comorbidity (anxiety, depression), insomnia, other chronic pain syndromes
- Dependence-related behaviours or concurrent sedative/tranquilizer use
- Female sex and family history of substance misuse or medication overuse headache
- Long duration of overuse before presentation
Clinical Features
Symptoms
- Headache on >=15 days/month, often daily or near-daily
- History of escalating headache frequency with rising acute medication intake
- Headache phenotype resembling underlying migraine or tension-type headache
- Morning-predominant headache in some patients
- Poor response to previously effective acute treatments
- Associated sleep disturbance, low mood, anxiety, reduced quality of life
Signs
- Often normal neurological examination
- No focal neurological deficit in uncomplicated MOH
- Possible medication dependence pattern on history (early repeat dosing, multiple drug classes overused)
- Look actively for red-flag signs suggesting alternative secondary headache (for example papilloedema, meningism, temporal artery tenderness, focal deficits)
Investigations
Management
Lifestyle Modifications
- Explain diagnosis clearly: headache is perpetuated by frequent acute medication use, not patient 'failure'
- Agree a withdrawal plan and stop overused acute medication(s); abrupt withdrawal is usually used, but taper opioids/benzodiazepine-containing medicines to reduce withdrawal risk
- Use a headache diary to track headache days, medication days, and relapse risk
- Address sleep, hydration, caffeine excess/withdrawal patterns, stress, and comorbid anxiety/depression
- Give relapse-prevention advice: limit future acute headache treatment to <=2 days/week where possible
Pharmacological Treatment
Withdrawal-phase symptomatic treatment (short term, avoid creating new overuse)
- Naproxen 250-500 mg twice daily with food for a limited rescue period (typically up to 1-2 weeks)
- Domperidone 10 mg up to three times daily as needed for nausea (short-term use)
Avoid replacing one overused medicine with another long-term. NSAIDs: caution/avoid in peptic ulcer disease, CKD, heart failure, anticoagulation; consider gastroprotection if risk is high. Domperidone: QT-prolongation/cardiac risk; use lowest dose for shortest duration and check contraindications/interactions.
Preventive therapy for underlying primary headache (commonly migraine) after or around withdrawal
- Propranolol 40 mg twice daily, titrate (usual 80-160 mg/day in divided doses)
- Topiramate start 25 mg at night, increase by 25 mg weekly to typical 50 mg twice daily
- Amitriptyline 10 mg at night, increase gradually (commonly 20-50 mg at night; sometimes up to 75 mg)
- Candesartan 4 mg once daily, titrate to 8-16 mg once daily (off-label for migraine prevention)
Choose by headache phenotype and comorbidity. Key cautions: propranolol contraindicated in asthma/bradycardia/heart block; topiramate is teratogenic risk and may impair cognition/mood, so avoid in pregnancy and counsel on effective contraception; amitriptyline causes anticholinergic effects/sedation and overdose toxicity; candesartan contraindicated in pregnancy and needs renal function/potassium monitoring.
Acute headache treatment after detoxification (strict limits)
- Sumatriptan 50-100 mg orally at onset (max 300 mg/24 h), restricted to <=2 days/week
- Paracetamol 1 g up to four times daily as needed, restricted to <=2 days/week
- Ibuprofen 400 mg up to three times daily as needed, restricted to <=2 days/week
Explicitly set monthly limits to prevent recurrence of MOH. Triptans are contraindicated in ischaemic heart disease, prior stroke/TIA, uncontrolled hypertension; avoid combining triptans with ergot derivatives.
Complications
- Progression from episodic to chronic migraine if untreated
- Persistent disability with reduced work, social, and family functioning
- Comorbid anxiety, depression, and sleep disturbance
- Relapse after successful withdrawal (common in first year)
- Adverse effects from long-term analgesic/opioid exposure (for example GI, renal, dependence-related harms)
Prognosis
Most patients improve after stopping overused medication, and many revert to an episodic primary headache pattern with better response to preventive therapy. Relapse is common, especially within the first year (about 22-45% at 1 year in guideline summaries), and risk is higher with opioid overuse, mixed migraine+tension phenotypes, longer overuse duration, and psychiatric/chronic pain comorbidity.
Sources & References
🏥BMJ Best Practice(1)
✅NICE Guidelines(1)
- Headache - medication overuse[overview]
📖Textbook References(11)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 958, 959)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 275, 276)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 275)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 960)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 275)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 959, 960)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 957, 958)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 960)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 276)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 896)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 895, 896)[context]